The aim of this study is to prospectively collect clinical information on patients with extranodal lymphoma, and to explore the best therapeutic strategies in the real-world population.
Age ≥ 18 years (including 18 years old).
Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement, whether it is primary, secondary, or cannot be determined.
Patients who have received systematic clinical treatment.
Patients with measurable lesions, at least containing one effective evaluation of efficacy.
Patients who only receive supportive treatment.
Patients who cannot obtain effective evaluation data of efficacy.